Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1987 Sep;84(18):6550–6554. doi: 10.1073/pnas.84.18.6550

Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease.

R B Levene, F M Booyse, J Chediak, T S Zimmerman, D M Livingston, D C Lynch
PMCID: PMC299116  PMID: 3306682

Abstract

Studies were conducted to characterize the biosynthesis of von Willebrand factor (vWf) by cultured endothelial cells (EC) derived from the umbilical vein of a patient with type IIA von Willebrand disease. The patient's EC, compared with those from normal individuals, produced vWf that had decreased amounts of large multimers and an increase in rapidly migrating satellite species, features characteristic of plasma vWf from patients with type IIA von Willebrand disease. The type IIA EC did produce a full spectrum of vWf multimers in both cell lysates and postculture medium, although the relative amounts of the largest species were decreased. The large multimers were degraded in conjunction with the appearance of rapidly migrating satellites that contained approximately equal to 170-kDa proteolytic fragments, suggesting that this patient's functional defect is due to abnormal proteolysis and not to a primary failure of vWf subunit oligomerization. Moreover, the observed degradation appears to result from an abnormal vWf molecule and not elevated protease levels. These results suggest that this patient's von Willebrand disease phenotype is caused by increased proteolytic sensitivity of his vWf protein.

Full text

PDF
6550

Images in this article

6551Image
on p.6551
6551Image
on p.6551
6551Image
on p.6551
6551Image
on p.6551
6551Image
on p.6551
6552Image
on p.6552
6553Image
on p.6553
6553Image
on p.6553

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batlle J., Lopez Fernandez M. F., Campos M., Justica B., Berges C., Navarro J. L., Diaz Cremades J. M., Kasper C. K., Dent J. A., Ruggeri Z. M. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors. Blood. 1986 Dec;68(6):1207–1212. [PubMed] [Google Scholar]
  2. Berkowitz S. D., Dent J., Roberts J., Fujimura Y., Plow E. F., Titani K., Ruggeri Z. M., Zimmerman T. S. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest. 1987 Feb;79(2):524–531. doi: 10.1172/JCI112843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Booyse F. M., Quarfoot A. J., Chediak J., Stemerman M. B., Maciag T. Characterization and properties of cultured human von Willebrand umbilical vein endothelial cells. Blood. 1981 Oct;58(4):788–796. [PubMed] [Google Scholar]
  4. Bowie E. J., Solberg L. A., Jr, Fass D. N., Johnson C. M., Knutson G. J., Stewart M. L., Zoecklein L. J. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest. 1986 Jul;78(1):26–30. doi: 10.1172/JCI112560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gralnick H. R., Williams S. B., McKeown L. P., Maisonneuve P., Jenneau C., Sultan Y., Rick M. E. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5968–5972. doi: 10.1073/pnas.82.17.5968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gunning P., Ponte P., Okayama H., Engel J., Blau H., Kedes L. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol Cell Biol. 1983 May;3(5):787–795. doi: 10.1128/mcb.3.5.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lynch D. C., Zimmerman T. S., Collins C. J., Brown M., Morin M. J., Ling E. H., Livingston D. M. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell. 1985 May;41(1):49–56. doi: 10.1016/0092-8674(85)90060-1. [DOI] [PubMed] [Google Scholar]
  8. Lynch D. C., Zimmerman T. S., Kirby E. P., Livingston D. M. Subunit composition of oligomeric human von Willebrand factor. J Biol Chem. 1983 Nov 10;258(21):12757–12760. [PubMed] [Google Scholar]
  9. Lynch D. C., Zimmerman T. S., Ling E. H., Browning P. J. An explanation for minor multimer species in endothelial cell-synthesized von Willebrand factor. J Clin Invest. 1986 Jun;77(6):2048–2051. doi: 10.1172/JCI112535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Maciag T., Hoover G. A., Stemerman M. B., Weinstein R. Serial propagation of human endothelial cells in vitro. J Cell Biol. 1981 Nov;91(2 Pt 1):420–426. doi: 10.1083/jcb.91.2.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ruggeri Z. M., Mannucci P. M., Lombardi R., Federici A. B., Zimmerman T. S. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982 Jun;59(6):1272–1278. [PubMed] [Google Scholar]
  12. Sporn L. A., Marder V. J., Wagner D. D. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986 Jul 18;46(2):185–190. doi: 10.1016/0092-8674(86)90735-x. [DOI] [PubMed] [Google Scholar]
  13. Thornton S. C., Mueller S. N., Levine E. M. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science. 1983 Nov 11;222(4624):623–625. doi: 10.1126/science.6635659. [DOI] [PubMed] [Google Scholar]
  14. Wagner D. D., Marder V. J. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983 Feb 25;258(4):2065–2067. [PubMed] [Google Scholar]
  15. Wagner D. D., Marder V. J. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol. 1984 Dec;99(6):2123–2130. doi: 10.1083/jcb.99.6.2123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wagner D. D., Mayadas T., Marder V. J. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986 Apr;102(4):1320–1324. doi: 10.1083/jcb.102.4.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wagner D. D., Mayadas T., Urban-Pickering M., Lewis B. H., Marder V. J. Inhibition of disulfide bonding of von Willebrand protein by monensin results in small, functionally defective multimers. J Cell Biol. 1985 Jul;101(1):112–120. doi: 10.1083/jcb.101.1.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wagner D. D., Olmsted J. B., Marder V. J. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982 Oct;95(1):355–360. doi: 10.1083/jcb.95.1.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zimmerman T. S., Dent J. A., Ruggeri Z. M., Nannini L. H. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest. 1986 Mar;77(3):947–951. doi: 10.1172/JCI112394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Zimmerman T. S., Ruggeri Z. M., Fulcher C. A. Factor VIII/von Willebrand factor. Prog Hematol. 1983;13:279–309. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES